Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.
相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2019
招募中
1
20.0%
终止
4
80.0%
暂无批准数据
- Qurient has signed a licensing agreement with Synaffix to develop a dual-payload ADC combining Qurient's CDK7 inhibitor mocaciclib with Synaffix's exatecan-based technology. - This represents the first known use of a CDK7 inhibitor as a dual payload in ADC development, addressing unmet medical needs in solid tumor treatment. - The collaboration leverages Synaffix's site-specific ADC platform and Lonza's manufacturing expertise to create a therapy designed to enhance efficacy and mitigate resistance in refractory cancers. - Dual-payload ADCs deliver two different mechanisms of action to targeted cancer cells, potentially expanding treatment scope while minimizing toxicity to healthy tissues.
- Cargo Therapeutics agreed to be acquired by Concentra Biosciences for approximately $202 million upfront after halting development of its lead CAR-T therapy firicabtagene autoleucel due to poor durability results. - The company's Phase II trial showed firi-cel achieved a 77% response rate but only 18% durability at three months, leading to rapid patient relapse and termination of the mid-stage study in January. - Concentra, backed by Tang Capital Partners, continues its acquisition strategy targeting distressed biotechs, having completed five buyouts in 2024 including Elevation Oncology and Kronos Bio. - The deal provides Cargo shareholders with 100% of net cash above $217.5 million at closing plus 80% of proceeds from asset sales within two years, effectively winding down the company that raised $200 million in 2023.
- Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights. - The acquisition represents the latest example of investment firms targeting struggling biotech "zombies" worth less than their cash reserves for liquidation rather than strategic repositioning. - Elevation's lead cancer drug disappointed in clinical testing, forcing the company to shelve its program, lay off most staff, and trade below $1 per share for nearly a year. - The deal follows Tang Capital's previous acquisitions of struggling biotechs including Allakos, Jounce Therapeutics, and Kronos Bio through its liquidation-focused investment strategy.
- Concentra Biosciences has entered into a definitive merger agreement to acquire Elevation Oncology for $0.36 in cash per share plus contingent value rights. - The contingent value rights include 100% of closing net cash exceeding $26.4 million and 80% of net proceeds from EO-1022 disposition within specified timeframes. - Elevation Oncology's Board of Directors unanimously approved the acquisition, with the tender offer expected to commence by June 23, 2025 and transaction closure anticipated in July 2025. - Company officers, directors and affiliates holding approximately 5.1% of common stock have signed agreements to tender their shares and support the merger transaction.
- CSPC Pharmaceutical Group revealed it is in talks with three parties for licensing deals worth up to $5 billion in potential fees, including a targeted cancer therapy and other novel drug candidates. - The announcement came after disappointing Q1 2024 results showing a 21.91% revenue drop to 7.02 billion yuan and 8.36% decline in net profit to 1.48 billion yuan. - The company has already completed two major licensing deals this year, including a $150 million upfront payment from BeiGene and a $15 million deal with Radiance Biopharma. - Chinese biotech licensing deals with multinational partners are surging, with lawyers reporting at least seven deals in 2023 and five already identified in 2024.
- Elevation Oncology initiated dosing of EO-3021, a Claudin 18.2 ADC, in combination with ramucirumab or dostarlimab for advanced gastric/GEJ cancer patients. - Additional monotherapy data from the Phase 1 trial of EO-3021 is expected in the first half of 2025, building on promising initial results. - Preclinical data for EO-1022, a HER3 ADC, will be presented in the first half of 2025, with plans to file an IND application in 2026. - Initial data from the combination cohorts of EO-3021 are anticipated in late 2025 or early 2026, evaluating synergistic benefits.
• Elevation Oncology's EO-3021 demonstrated a 42.8% confirmed objective response rate (ORR) in Claudin 18.2-enriched gastric and GEJ cancer patients. • The Phase 1 trial of EO-3021 has progressed into the dose expansion phase, with additional monotherapy data expected in the first half of 2025. • Combination trials of EO-3021 with VEGFR2 and PD-1 inhibitors are set to begin in Q4 2024, with preclinical data presented at ESMO-IO 2024. • The FDA granted Fast Track designation to EO-3021 for advanced or metastatic gastric and GEJ cancers expressing Claudin 18.2 after prior therapy.
• Elevation Oncology's EO-3021 demonstrated a 42.8% confirmed objective response rate (ORR) in Claudin 18.2-enriched gastric and GEJ cancer patients in Phase 1 trials. • Preclinical data presented at ESMO-IO 2024 supports the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors, showing synergistic anti-tumor activity. • The FDA granted Fast Track designation to EO-3021 for advanced or metastatic gastric and GEJ cancer expressing Claudin 18.2, expediting its development. • Elevation Oncology plans to initiate dosing in the combination portion of the Phase 1 trial of EO-3021 in Q4 2024, with additional monotherapy data expected in 1H 2025.
• The FDA has granted Fast Track designation to EO-3021 for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancer expressing Claudin 18.2. • EO-3021, a differentiated antibody-drug conjugate, targets Claudin 18.2, a protein exposed in malignant transformation of gastric epithelial cells. • The Fast Track designation aims to expedite the development and review of EO-3021, offering potential for priority review and accelerated approval. • Early Phase 1 trial results showed a 42.8% overall response rate in a Claudin 18.2-enriched subset of gastric and GEJ cancer patients.
